Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Purchased by Forbes J M & Co. LLP

Forbes J M & Co. LLP grew its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 461.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 701,732 shares of the company's stock after buying an additional 576,732 shares during the period. Forbes J M & Co. LLP owned 1.22% of Ginkgo Bioworks worth $6,891,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. KBC Group NV acquired a new position in shares of Ginkgo Bioworks in the 4th quarter valued at $31,000. SG Americas Securities LLC acquired a new position in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $199,000. Point72 Asia Singapore Pte. Ltd. raised its stake in Ginkgo Bioworks by 644.5% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 32,319 shares of the company's stock valued at $263,000 after purchasing an additional 27,978 shares during the last quarter. FNY Investment Advisers LLC lifted its holdings in Ginkgo Bioworks by 125.6% in the 4th quarter. FNY Investment Advisers LLC now owns 75,966 shares of the company's stock valued at $745,000 after purchasing an additional 42,298 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new stake in Ginkgo Bioworks during the 3rd quarter worth $792,000. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Stock Down 0.6 %

Shares of Ginkgo Bioworks stock traded down $0.07 on Wednesday, hitting $12.31. 1,767,045 shares of the company were exchanged, compared to its average volume of 1,577,483. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.26 and a 1-year high of $64.40. The stock has a market cap of $707.57 million, a PE ratio of -0.94 and a beta of 1.16. The stock's 50-day moving average is $11.12.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.